For a link to the full document click here
AUSTIN, Texas, March 12, 2019– Vermillion, Inc. (Nasdaq: VRML),a bioanalytical-based women’s health company focused on gynecologic disease, today announced that it will report financial results for the fourth quarter and year ended December 31, 2018 on Thursday, March 28, followed by an investor conference call and webcast at 4:30 p.m. Eastern Time.
Thursday, March 28th@ 4:30pm Eastern Time
Conference ID: 13688624
About Vermillion, Inc.
Vermillion, Inc. is dedicated to the discovery, development and commercialization of novel high-value diagnostic and bio-analytical solutions that help physicians diagnose, treat and improve gynecologic health outcomes for women. Vermillion, along with its prestigious scientific collaborators, discovers, develops, and delivers innovative diagnostic and technology tools that help women with serious diseases. The company’s initial in vitro diagnostic test, OVA1® (MIA), was the first FDA-cleared, protein-based In Vitro Diagnostic Multivariate Index Assay, and represented a new class of software-based liquid biopsy in vitro diagnostics. In March 2016, Vermillion received FDA clearance for Overa™, a Multivariate Index Assay 2nd Generation (MIA2G) test with significantly improved specificity and ease of use. For additional information, including published clinical trials, visit www.vermillion.com.
Visit our website for more information about our products at www.vermillion.com.
Investor Relations Contact:
Ashley R. Robinson
LifeSci Advisors, LLC